Summary
Complementary and alternative medicine (CAM) is widely used but weakly measured as a market. The sources show high reported use. Most WHO member States report that 40 to 90 percent of their populations use traditional medicine 3, and 63.1 percent of Australian adults reported any complementary medicine use 6. Spending is visible in the United States, where Americans spend about 30.2 billion US dollars a year out of pocket on complementary health products and practices 8. Global market value, practitioner headcounts, waiting times and reimbursement rules were not verified in the pack. The main findings are high use, uneven evidence and a policy push toward regulation and integration 2. Principal risks include safety data gaps, unquantified product quality issues and household cost exposure. The outlook is incremental: integration will advance unevenly, and stakeholders need comparable data before making market-sizing or investment decisions.
Key findings
-
1
Reported use of traditional medicine is high across member States
WHO member States report that 40 to 90 percent of their populations use traditional medicine. The figure comes from a news report of member State reports and is not a standardized prevalence measure for CAM.
Confidence: Medium -
2
US consumers pay a sizeable out-of-pocket amount for complementary health
Americans spend about 30.2 billion US dollars a year out of pocket beyond insurance coverage. This equals 9.2 percent of all out-of-pocket health spending and 1.1 percent of total health spending.
Confidence: High -
3
Product use in Australia exceeds practitioner use
63.1 percent of Australian adults reported any complementary medicine use. Vitamin or mineral supplements were used by 47.8 percent, while 36 percent consulted a complementary medicine practitioner.
Confidence: High -
4
Clinician use of CAM is substantial
A pooled estimate across 15 years of studies found 45 percent of medical specialists use CAM, with a 95 percent confidence interval of 37 to 54 percent. Obstetrics and gynecology reported the highest use at 68 percent.
Confidence: High -
5
Policy ambition is not matched by reported funding commitments
The WHO strategy sets objectives for evidence, regulation, integration and cross-sector value, but a news analysis reports it contains no funding figures and no pledges for further research investment. This is a qualitative assessment.
Confidence: Qualitative
1Industry definition and scope
This report treats complementary and alternative medicine (CAM) as health practices used alongside or outside mainstream conventional care. The sources use overlapping terms. WHO uses traditional, complementary and integrative medicine 12, the US National Center for Complementary and Integrative Health uses complementary and integrative health 89, and peer-reviewed studies use CAM 567. These terms are not defined identically, so comparisons across sources carry definitional risk.
The segments covered in the pack are practitioner-delivered services, self-care products such as vitamin and mineral supplements 6, and traditional medicine knowledge that links to pharmaceutical development. For the last segment, the pack contains only a WHO statement, as reported in news coverage, that about 40 percent of pharmaceutical products have origins in traditional medicine 4.
Geography is global, with four national examples: the United States, Australia, Brazil and the United Kingdom. The pack contains no verified United Kingdom figures, so that market is described only qualitatively. The reporting period is the latest available data. Survey periods differ across sources and are not uniform, so the figures should be read as indicative rather than strictly comparable.
2Market size, structure and value chain
No globally comparable market size or revenue figure for CAM products and practitioner services was verified. WHO and NCCIH sources report spending or funding rather than a global market value. Readers should not infer a global market total from the figures below.
The most concrete spending indicator comes from the United States. Americans spend about 30.2 billion US dollars a year out of pocket on complementary health products and practices beyond insurance coverage 8. This equals 9.2 percent of all out-of-pocket health spending and 1.1 percent of total health spending 8. The NCCIH page is undated, so the figure is treated as the latest available estimate.
Public research funding is a different measure. NCCIH, the federal lead agency for scientific research on complementary and integrative health approaches within NIH 9, reported funding of 170.3 million US dollars for its most recent fiscal year cited 9. This is a research budget, not a measure of service revenue, and it should not be compared directly with consumer spending.
The value chain, as an interpretation of the sources, runs from ingredient and raw material supply, through product manufacture and retail or online sale, to practitioner services and referral. The pack supports the link from consumer purchase to out-of-pocket payment 8 and from traditional medicine knowledge to pharmaceutical development 4. Supplier structure, margins and revenue models were not verified.
Key stakeholders include consumers, practitioners, product suppliers, national research agencies such as NCCIH 9 and WHO as a global policy body 2. Their relative economic weight cannot be ranked from the pack.
- Out-of-pocket spending on complementary health products and practices 30.2billion US dollars per year Observed United States, Latest NCCIH estimate [8]
- Share of all out-of-pocket health spending 9.2percent Observed United States, Latest NCCIH estimate [8]
- Share of total health spending 1.1percent Observed United States, Latest NCCIH estimate [8]
- NCCIH research funding 170.3million US dollars Observed United States, Most recent fiscal year cited by NCCIH [9]
KPIs are taken directly from NCCIH publications. No global market value was constructed because the pack does not support one.
Assumptions behind these figures
- The NCCIH spending estimate is treated as the latest available figure because the page does not show a date.
- Out-of-pocket spending and federal research funding measure different things and are not added or ratioed.
3Customers, demand and adoption
Use is high, but it varies by population and by measurement method. WHO reports that most member States say 40 to 90 percent of their populations use traditional medicine 3. A Brazilian peer-reviewed study cites a worldwide CAM use range of 10 to 75 percent of the general population 5. The width of that range reflects different definitions, survey designs and periods, so it is a limited guide to a single figure.
National survey data give more precise values. In Australia, 63.1 percent of adults reported any complementary medicine use. Vitamin or mineral supplements were the most used product at 47.8 percent, and 36 percent consulted a complementary medicine practitioner 6. Product use is therefore far more common than practitioner use, which points to self-directed purchasing as a main demand channel.
Among clinicians, a systematic review of 15 years of studies gives a pooled estimate that 45 percent of medical specialists use CAM, with a 95 percent confidence interval of 37 to 54 percent 7. Obstetrics and gynecology reported the highest use at 68 percent 7. This is a measure of clinician use, not patient demand, and it may not transfer to other settings.
Self-care for chronic conditions is a demand driver. A CDC-published analysis reports that more than a quarter of American adults have two or more chronic conditions and that many use CAM for self-care despite a limited evidence base 10. Multivitamins, multiminerals or both were the most common use, at 52.7 percent of the chronic conditions sample studied 10.
Purchasing criteria, price sensitivity by income and changing consumer expectations were not verified in the sources. WHO's strategy envisions universal access to people-centred traditional, complementary and integrative medicine 2. This implies that current access is uneven, but the pack does not quantify access. Interpretation: demand appears driven by self-care and perceived accessibility, but the sources do not measure this directly.
| Group | Measure | Reported value (percent) | Source ID |
|---|---|---|---|
| Australian adults | Any complementary medicine use | 63.1 | S6 |
| Australian adults | Vitamin or mineral supplement use | 47.8 | S6 |
| Medical specialists, multi-country | Pooled CAM use | 45 | S7 |
| Obstetrics and gynecology specialists | CAM use | 68 | S7 |
| US adults with chronic conditions | Multivitamin or multimineral use | 52.7 | S10 |
| WHO member States | Population using traditional medicine (range across reports) | 40 to 90 | S3 |
Table values are copied from sources and grouped by population. They differ in definition, period and sampling, so no average or trend is calculated.
4Competitive landscape and key players
The pack does not name commercial companies that sell CAM products or services, and it gives no market share data. Comparable company examples were therefore limited. This section compares provider types instead, which is a fairer basis given the sources available.
Public institutions set direction and fund research rather than sell services. WHO's strategy aims for an evidence base, safe and effective provision through regulation, integration into health systems and cross-sector value 2. NCCIH funds and coordinates US federal research on these approaches 9. Their role is standard-setting, research and policy, not service delivery.
Private and community provision is largely outside formal structures. WHO reports that most traditional, complementary and integrative medicine practitioners work outside formal programs for such providers 1. The pack does not quantify this share or describe regional differences, so the finding should be treated as a global pattern with limited detail.
Product suppliers are a large part of the consumer market. Vitamin and mineral supplements were the most used complementary product in Australia 6. The pack does not identify supplier concentration, brands or pricing. WHO's statement that about 40 percent of pharmaceutical products have origins in traditional medicine 4 indicates a research link, but it is reported second-hand and does not describe commercial competitors.
Competitive pressures, as interpretation, center on differentiation through perceived naturalness and personal access rather than verified outcomes. A peer-reviewed analysis notes that many users rely on CAM despite a limited evidence base 10. Vendor claims were not in the pack and have not been assessed. Market concentration cannot be assessed from the sources.
Comparison is by provider type because no company-level data were verified.
5Technology, operations and workforce
The pack describes few clinical technologies. The notable infrastructure is knowledge-based. WHO launched a global traditional medicine library with over 1.6 million scientific records alongside its strategy 3. This is an evidence resource, not a clinical technology, and its usage data were not verified.
Digital health adoption, telehealth and CAM applications were not verified in the pack. This is a significant gap for any assessment of access, and it is recorded in the limitations.
The workforce picture is incomplete. The pack gives no current practitioner headcount, training capacity or staffing ratios. WHO's finding that most practitioners work outside formal programs 1 signals a workforce that is difficult to count and oversee. The strategy's objective of integration into health systems 2 implies a need for training, recognition and referral pathways, but the sources give no capacity figures.
Operations and productivity indicators are also missing. No waiting-time, throughput, cost-per-visit or staffing productivity data were verified for CAM services. Safety reporting and adverse-event data were not quantified.
Business-model change is a plausible interpretation rather than a finding. Integration into health systems could shift practitioner income from direct cash payment toward formal referral and reimbursement. The pack does not verify reimbursement rules outside the United States, so this remains an assumption for stakeholders to test.
6Regulation, standards, risk and sustainability
Jurisdiction matters. WHO's strategy sets safe and effective provision through regulation as one of its four objectives 2. WHO is a global body, so the strategy is a policy framework and not a binding law in any country. The pack does not confirm the binding national rules for CAM in the United States, Australia, Brazil or the United Kingdom, so this report does not describe them.
Evidence standards are a central concern. The first WHO strategy objective concerns the evidence base 2. A peer-reviewed analysis notes that many users rely on CAM despite a limited evidence base 10. NCCIH's role includes scientific research on these approaches 9. Evidence standards for specific products or practitioners were not verified.
Safety is under-measured. Safety reporting and adverse-event data for CAM products were not quantified in the retrieved sources. Supplement use is high in Australia 6, so product quality and safety affect a large user group. The pack gives no safety incidence figures.
Privacy and ethics: this report uses only aggregated survey and published data and does not describe individual patients. Clinician use of CAM 7 raises professional standards questions, but the sources do not examine how those standards are applied.
Sustainability and social factors are only indirectly covered. WHO's cross-sector value objective 2 is the closest reference. No environmental data were verified. Equity indicators beyond US race and ethnicity patterns were not verified for a current period.
Financial risk is material for households. Out-of-pocket spending equals 9.2 percent of all out-of-pocket health spending in the United States 8. The sources do not show how this burden is distributed by income or insurance status.
Regulatory statements reflect only the WHO strategy in the pack. National binding rules are not described.
7Challenges, opportunities and case examples
Example 1, WHO traditional medicine strategy: WHO's strategy sets four objectives and envisions universal access to people-centred care 2. It was launched with a global library of over 1.6 million scientific records 3. A news analysis reports the strategy contains no funding figures and no pledges for further research investment 4. This illustrates ambition with unquantified resourcing.
Example 2, NCCIH in the United States: NCCIH is the lead federal research agency for complementary and integrative health 9, with funding of 170.3 million US dollars in its most recent fiscal year cited 9. Americans spend about 30.2 billion US dollars a year out of pocket on these products and practices 8. Comparing the two shows that public research funding is small relative to consumer spending. This comparison is an interpretation, not a standardized ratio.
Example 3, Australian national survey: a nationally representative survey found 63.1 percent of adults used complementary medicine, and 36 percent consulted a practitioner 6. This shows that product use is more common than practitioner use.
Example 4, Brazil national health survey: a peer-reviewed study used the national health survey to estimate CAM use among adults over the previous 12 months 5. Its main contribution is a national estimation method that other countries could replicate.
Constraints include evidence gaps, unquantified safety, household cost exposure and a workforce that is hard to measure. Opportunities include integration into health systems as WHO envisages 2, research investment if funding is committed, and a large self-care market with high use 6. The opportunity assessment is interpretation based on the sources.
Case examples are drawn from public bodies and surveys because comparable company examples were limited in the pack.
8Outlook and strategic implications
Near term, expect continued high use and growing policy attention. WHO's strategy frames integration and regulation as priorities 2. The strategy's uncertain resourcing 4 suggests progress will be incremental and uneven across countries. This is the most likely scenario based on the sources, not a forecast from them.
Medium term, integration will depend on evidence, regulation and funding. Key uncertainties include national rules, reimbursement, safety data and whether consumer spending shifts toward regulated services. The pack contains no market forecast, so growth cannot be quantified.
Implications for stakeholders: industry participants should treat market claims as unverified until comparable data exist. Regulators need clear standards for products and practitioners. Researchers face an evidence gap in many areas 10. Payers and households face cost exposure 8. These are general implications, not individual medical or investment advice.
9Conclusion
The evidence shows high and widespread CAM use, a measurable US out-of-pocket spending base and a policy push toward integration 28. Market size, workforce capacity, reimbursement and safety data remain unverified. The most defensible takeaway is that use is high, evidence is uneven and comparable data are the main constraint.
How this was built
This report uses only the verified source pack. Figures are copied from sources and labeled by valueType. Survey periods and definitions differ, so cross-source comparisons are indicative. No market size, forecast or company share was constructed because the pack does not support them.
Limits to keep in mind
- No globally comparable market size or revenue data for CAM products and practitioner services was verified.
- No current waiting-time, practitioner headcount or workforce capacity figures by country were verified.
- Reimbursement rules for CAM practitioners outside the United States were not verified.
- Digital health adoption and CAM app or telehealth indicators were not verified.
- Safety reporting and adverse-event data for CAM products were not quantified.
- Equity indicators beyond US race and ethnicity patterns were not verified for a current period.
Sources
-
1
WHO global report on traditional, complementary and integrative medicine, latest edition
iris.who.int -
2
WHO Traditional Medicine Strategy, current period (WHO Traditional, Complementary and Integrative Medicine topic page)
who.int -
3
Traditional medicine use is now a global reality: WHO
news.un.org -
4
Health Policy Watch: WHO's big push to integrate traditional medicine
healthpolicy-watch.news -
5
Prevalence of complementary and alternative medicine use in Brazil: results of the National Health Survey
ncbi.nlm.nih.gov -
6
Complementary medicine use in the Australian population: Results of a nationally-representative cross-sectional survey
nature.com -
7
Acceptance and use of complementary and alternative medicine among medical specialists: a 15-year systematic review and data synthesis
systematicreviewsjournal.biomedcentral.com -
8
Paying for Complementary and Integrative Health Approaches
nccih.nih.gov -
9
NCCIH Congressional Justification, latest fiscal year, and About NCCIH
nccih.nih.gov -
10
Multiple Chronic Conditions and Use of Complementary and Alternative Medicine Among US Adults: Results From the National Health Interview Survey, latest edition
cdc.gov